ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week High – Still a Buy?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price reached a new 52-week high on Friday . The company traded as high as $22.30 and last traded at $21.67, with a volume of 779556 shares changing hands. The stock had previously closed at $19.72.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ADMA shares. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Up 13.5 %

The stock has a market cap of $5.22 billion, a price-to-earnings ratio of 154.79 and a beta of 0.64. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock has a fifty day moving average of $18.01 and a two-hundred day moving average of $13.73.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same quarter last year, the firm posted ($0.02) earnings per share. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insider Activity

In related news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the business. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics during the third quarter valued at about $30,000. Quest Partners LLC bought a new stake in shares of ADMA Biologics during the 2nd quarter worth about $29,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $31,000. USA Financial Formulas boosted its holdings in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 539 shares in the last quarter. Finally, CWM LLC increased its stake in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.